Invex Therapeutics
Subiaco
About Invex Therapeutics
Invex is a biopharmaceutical company focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure, such as Idiopathic Intracranial Hypertension (IIH), acute stroke and traumatic brain injury.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1 – 10
- Total funding: $26.0M
- Funding stage: IPO
- Last round: Post-IPO Equity (May 2020)
- Ticker: asx:IXC
- Website: invextherapeutics.com
- Phone: +61 (08) 6382 0137
Industries & Categories
Biopharma, Biotechnology, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/invex-therapeutics-171731 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.